BioXell informs about Supplement Consideration by Cosmo
(Thomson Reuters ONE) -
bioXell S.p.A / BioXell informs about Supplement Consideration by Cosmo processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement.
Milan, Italy, 10 March 2010 - Cosmo Pharmaceuticals S.p.A. today informed that
the supplement consideration according to section B.3.d) of the Offer Prospectus
(as published by Cosmo Pharmaceuticals S.p.A. on 8 December 2009) amounts to
? 500,000 (Euro five hundred thousand) or an equivalent of CHF 0.13591 per
BioXell Share tendered within the Offer. Such supplement consideration will be
paid at the execution of the Offer on 11 March 2010 as part of the Offer
consideration defined in section B.3.a) of the Offer prospectus.
About BioXell
BioXell S.p.A., a listed biopharmaceutical company focused on the discovery and
development of drugs that exploit novel mechanisms of action, announced on 18
November 2009 that it had entered into a transaction agreement with Cosmo
Pharmaceuticals S.p.A. (SIX Swiss Exchange: COPN), headquartered in Lainate,
Italy. After a comprehensive and careful review of all available strategic
options and a thorough review of the terms of the proposed offer, BioXell's
Board of Directors concluded unanimously that Cosmo's intended acquisition is in
the best interests of BioXell's shareholders.
The detailed terms of the tender offer were set out in Cosmo's offer prospectus
on 8 December 2009, which can be downloaded at www.cosmopharmaceuticals.com
11 March 2010.
BioXell was founded in 2002 as a spin-out from Roche. In June 2006, BioXell
listed its shares on the main segment of the SIX Swiss Exchange. The company is
located in Milan, Italy.
For further information, please contact:
BioXell Dynamics Group SA
Alvise Sagramoso, Chief Administrative Christophe Lamps
Officer
Tel: +39 (0)2 210 49 550 Tel: +41 (0)22 308 62 22
Fax: +39 (0)2 700 59 926 Fax: +41 (0)22 308 62 36
alvise.sagramoso(at)bioxell.com cla(at)dynamicsgroup.ch
Disclaimer
This document does not constitute, or form part of, any offer to purchase or
sell any shares or other securities and neither it nor any part of it shall form
the basis of, or be relied upon in connection with any contract or commitment
whatsoever. Any decision to tender shares must be based on the official offer
documents. This document does also not constitute a pre-announcement or an
offering prospectus pursuant to Swiss laws or any other laws.
This press release does not constitute or form part, or all, of any offer or
invitation to sell or issue, or any solicitation of any offer to purchase or
subscribe for, any securities, nor shall part, or all, of these materials or
their distribution form the basis of, or be relied on in connection with, any
contract or investment decision in relation to any securities. This press
release contains forward-looking statements based on the currently held beliefs
and assumptions of the management of BioXell, which are expressed in good faith
and, in their opinion, reasonable. Forward-looking statements involve known and
unknown risks, uncertainties and other factors, which may cause the actual
results, financial condition, performance, or achievements of BioXell, or
industry results, to differ materially from the results, financial condition,
performance or achievements expressed or implied by such forward-looking
statements. Given these risks, uncertainties and other factors, recipients of
this document are cautioned not to place undue reliance on these forward-looking
statements. BioXell disclaims any obligation to update these forward-looking
statements to reflect future events or developments.
[HUG#1392315]
--- End of Message ---
bioXell S.p.A
via Olgettina 58 Milan Italy
WKN: A0J3MW;ISIN: IT0004069933 ;
Listed: Open Market (Freiverkehr) in Frankfurter Wertpapierbörse,
Freiverkehr in Bayerische Börse München;
English version PDF: http://hugin.info/133681/R/1392315/349928.pdf
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 10.03.2010 - 01:00 Uhr
Sprache: Deutsch
News-ID 1011127
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
Milan
Phone:
Kategorie:
Business News
Anmerkungen:
Diese Pressemitteilung wurde bisher 113 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"BioXell informs about Supplement Consideration by Cosmo
"
steht unter der journalistisch-redaktionellen Verantwortung von
bioXell S.p.A (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
